The Future of Pharmaceutical Benefit Management
JW Marriott Washington DC – Salon D
1331 Pennsylvania Ave, NW, Washington, DC 20004
June 9, 2015

7:30 a.m.  Breakfast

8:15 a.m.  Welcome and Introduction

Specialty drug costs are climbing by more than 15 percent annually, raising concern about the ability to pay for these treatments as the nation works to control total health spending growth. This Forum will examine how payers, providers and policy makers are using pharmaceutical benefits management, not only to manage spending, but also to ensure appropriate access to specialty medications to improve quality and value.

Stuart Altman, Ph.D., Professor of National Health Policy, Brandeis University

8:30 a.m.  The Pharmaceutical Product Landscape and the Evolution of Pharmaceutical Benefit Management

This session will discuss the specialty drug pipeline, pricing trends and efforts to ensure appropriate utilization. It will also provide a profile of the rapidly changing pharmaceutical benefit management sector and the strategies now being used to manage spending and ensure quality of care for best practice value.

Presenters:  Dan Mendelson, President, Avalere Health
Panelist:  Scott Howell, Sr. Vice President, Specialty Services, Cardinal Health

9:30 a.m.  Approaches for Managing Specialty Pharmaceutical Spending and Improving Outcomes

This session will discuss CVS/Caremark approaches to managing specialty pharmaceuticals including formulary design, prior authorization, step therapy, administration at lower cost sites as well as other novel approaches now being developed.

Presenter:  Troyen Brennan M.D., Chief Medical Officer, CVS Health
Panelist:  Kirsten Axelsen, Vice President, Worldwide Policy, Pfizer

10:45 a.m.  Break
11:15 a.m.  A Value Framework for Evaluating New Pharmaceutical Products

This session will discuss a value framework developed by ICER that examines the clinical effectiveness, cost effectiveness and budget impact of new medications. Participants will discuss trade-offs faced by payers and patients when new therapies are cost effective but have prohibitive health care budgets impacts.

Presenter:  Steven Pearson, M.D., President, Institute for Clinical and Economic Review

Panelists:  Edmund Pezalla, M.D., M.P.H., V.P. and National Medical Director, Aetna
           Robert Dubois, M.D., Ph.D., Chief Science Officer, National Pharmaceutical Council

12:30 p.m.  Lunch

1:00 p.m.  Managing Oncology Therapies: The Next Frontier for Pharmaceutical Benefit Management.

Twenty-two new cancer therapies have entered the market over the last two years and the average cost for branded oncology drugs is now about $10,000 per month according to IMS health. Newly launched treatments may offer only months of incremental survival, on average, over existing therapies but managing the use of these treatments is challenging due to high variability in patient response and concerns about patient equity. This session will examine emerging approaches for managing oncology care including new payment models, new modes of delivery emphasizing evidence-based protocols and efforts to administer medications at economical care sites.

Presenter:  Roy Beveridge, M.D., Chief Medical Officer, Humana

2:15 p.m.  Meeting adjourns